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Design and evaluation of Carbamazepine lozenzes 
 
Abstract:  
Lozenges are the flavoured solid, unit dosage medicated dosage formsusually in the sweetened 
base intended to be sucked and held in the mouth or pharynx containing one or more 
medicaments.  Lozenges were developed in 20
th
 century and is still under commercial 
production. These are medicated confections designed for local as well as systemic therapy. 
Carbamazepine (CBZ) is an anticonvulsant drug used in the treatment of epilepsy and 
neuropathic pain. It is used in schizophrenia along with other medications. 
In the present study an attempt has been made to prepare and evaluate the sugar based medicated 
Carbamazepine lozenzes to  improve bioavailability and increase patient compliance specially 
for those patients who have difficulty in swallowing. The lozenges were prepared using sucrose 
as base; HPMC K4M, methyl cellulose were used as polymers. Eudragit was used as taste 
masking agent. Formulations were prepared by heating and congealing method on laboratory 
scale 
All the formulations prepared were subjected to variousphysicochemical parameters like 
hardness, friability, weight variation,  drug content and in vitro dissolution studies.  
Stability studies of selected formulations of batch CL4 were also carried out at 40/75% relative 
humidity for 6 months for a period of six months. There wasn’t any substantial interaction 
between the drugs, flavor and color and other parameters and the prepared formulations were 
found to be stable. 
Keywords: Lozenges, HPMC K4M, Carbamazepine (CBZ), swallowing, in vitro dissolution, 
stability studies. 
 
Introduction 
The word "Lozenge" is derived from French word "Losenge" which indicates a diamond shaped 
geometry with four equal sides
1
. Lozenges are the flavouredmedicated solid, unit dosage forms 
intended to be sucked and held in the mouth or pharynx containing one or more medicaments 
usually in the sweetened base
2
. They dissolve slowly in the mouth and so release the drug 
dissolved in the saliva. The drugs having a large dose can be easily administered formulating as 
lozenges. The oral route of drug administration is most preferred route because of many 
advantages associated with it like ease of ingestion, pain avoidance, versatility and most 
important patient compliance
3
. However geriatric and pediatric patients suffer from dysphagia 
(difficulty in swallowing), thus oral route for drug administration is not suitable in these cases. 
There are other conditions in which oral route is not preferred like unavailability of water, 
sudden episodes of allergic attack, mentally retarded patients
4
. 
Most of the lozenge preparations are available as over the counter medications.  The dosage form 
can be adopted for local as well as systemic therapy and a wide range of drugs like analgesics, 
anesthetics, antimicrobials, antiseptics, antitussives, aromatics,astringents, corticosteroids, 
decongestants, demulcents and other can be delivered in the form of lozenges
5
. Lozenges are 
associated with many advantages like avoidance of first pass hepatic metabolism, no need of 
water intake, reduction in gastric irritation, improved bioavailability with reduced dosing 
frequency to minimum side effects
6
. 
Carbamazepine (CBZ) is an anticonvulsant is a medication used primarily in the treatment of 
epilepsy and neuropathic pain
7
. It is used in schizophrenia along with other medications and as a 
 second line agent in bipolar disorder. Carbamazepine is relatively slowly but well absorbed after 
oral administration
8
,
9
. 
In present study lozenges of Carbamazepine were prepared in order to improve bioavailability 
and increase patient compliance. 
Materials and methods  
Carbamazepine was obtained from Reals Pharmaceuticals Limited, Lagos, Nigeria. Eudragit E 
100 , methyl cellulose, Polyethylene glycol 8000 and HPMC K4M wereobtained from AC drugs 
ltd (Enugu, Nigeria). Sucrose and dextrose were provided by McNichols Plc, Ogun State, 
Nigeria. Citric acid was obtained from Mekz Global Limited ( Lagos) 
Preparation of Carbamazepine lozenges 
Carbamazepine lozenges were prepared in laboratory scale by heating and congealing technique, 
the composition as given in table 1. Required quantity of all ingredients were transferred into a 
copper bowl, and then heated in a heating mantle at 150°C for 15 minutes. Then the temperature 
of the mixture was brought into 90°C, then Carbamazepine, polymers, flavoring agent and 
coloring agent were added with stirring by using glass rod, and the solutionwas transferred into a 
lubricated mould. It was allowed to cool for solidification thenlozenges were collected and 
packed in an aluminum foil
10
.  
 
Table 1: Compostion of Carbamazepine lozenges 
Ingredients 
       (mg) 
Batch Code 
CL1 CL2 CL3 CL4 
Carbamazepine 10 10 10 10 
Eudragit E 100 10 15 20 25 
HPMC K4M 25 20 15 10 
Sucrose 800 740 730 700 
Dextrose - - 30 60 
Polyethylene glycol 
8000 
200 250 300 350 
Methylcellulose 25 20 15 10 
Citric acid 30 30 30 30 
Aspartame 100 100 100 100 
Talc 0.0126 0.0126 0.0126 0.0126 
Coloring agent 0.5 0.5 0.5 0.5 
Menthol 25 25 25 25 
 
Evaluation parameters of Carbamazepine Lozenges 
1. Measurement  of  thickness  
The thickness of Carbamazepine lozenges were determined using Vernier callipers. Three 
lozenges from each batch were used and average values were calculated
11
. 
2. Weight variation  
The formulated Carbamazepine lozenges were tested for weight uniformity. Twenty 
formulations were collectively and individually weighed. Fromthe collective weight, average 
weight was calculated. Each lozenge weight was then compared with average weight to ascertain 
whether it is within permissible limits or not
12
.  
3. Hardness 
The lozenge crushing strength, which is the force required to break the lozenge by compression 
in the diametric direction. The hardness of the Carbamazepine lozenges was determined by using 
 Monsanto Hardness tester, where the force required to break the lozenges was noted. It is 
expressed in kg/cm
2
. Ten formulations of each batch were used for theestimation of hardness
13
. 
4. Friability: 
The Roche friability test apparatus was used to determine the friability of the lozenges. Six pre 
weighed Carbamazepine lozenges were placed in the apparatus, for 4 min at 25 rpm. Then the 
lozenges were reweighed. The percentage friability was calculated by using the formula
14
.  
% Friability=(Initial weight-Final weight)/(Initial weight)  X100 
5. Drug content 
Three Carbamazepine lozenges from each batch wereselected and weighed individually and 
crushed in a mortar. Drug was extracted with 100 ml of distilled water. The drug content was 
determined spectrophotometrically at 285 nm with blank lozenge extract as the reference. The 
formulated lozenges were evaluated for the following parameters
15
. 
6. In vitro dissolution studies 
In vitro dissolution studies of Carbamazepine lozenges were carried out in 900 ml phosphate 
buffer pH6.8 using USP dissolution testing apparatus with a rotating stirrer speed at 100 rpm, 
and temperature of dissolution medium maintained at 37± 0.5°C. The rpmof the paddle was fixed 
at 100. Aliquots of 5ml were withdrawn at regular intervals; filtered and same amount of fresh 
dissolution medium was replaced at the same temperature. The filtered solutions were analyzed 
by using (Shimadzu, Japan) UV- spectrophotometer at 285 nm
16
. 
7. Disintegration test 
The disintegration time of Carbamazepine lozenges were determined by USP Disintegration 
apparatus and disintegration time was noted in buffer of pH 6.4 at 37
o
C
17
. 
8. Stability test 
For accelerated stability study, selected formulation was kept in airtight darkcontainer according 
to ICH guidelines at 40/75% relative humidity for 6 months
18
. 
Results and discussion:  
 
Physical appearance of prepared Carbamazepine lozenges 
 
 
 
 
 
 
 Table 1-Evaluation parameters for Carbamzepine lozenges formulations 
Batch 
code 
Thickness 
(cm) 
Hardness 
(Kg/cm
2
) 
% Weight 
variation 
% 
Friability 
% Drug 
content 
Disintegration 
time (min) 
CL1 14.32± 0.08 15.95± 0.13 3.25± 0.14 0.96± 0.07 96.72± 0.09 25±0.2 
CL2 14.50± 0.06 16.43± 0.18 2.42± 0.07 0.93± 0.13 95.28± 0.12 24±0.1 
CL3 14.38± 0.16 16.35± 0.08 4.51± 0.08 0.94± 0.25 97.47± 0.43 21±0.2 
CL4 14.23± 0.12 16.47± 0.08 2.34± 0.12 0.95± 0.18 99.82± 0.52 20±0.3 
 
Four different formulations of Carbamazepine lozenges were prepared successfully in laboratory 
scale by heating and congealing technique. Different ingredients i.e. Eudragit E 100, HPMC 
K4M, sucrose, dextrose, polyethylene glycol 8000, methylcellulose,citric acid, aspartame, talc, 
coloring agent, menthol were incorporated  in different ratio. In the Carbamazepine lozeges 
formulations menthol was used as flavoring agent, it provides a desirable soothing effect.   
All the formulations showed good physical appearance. The prepared tramdol hydrochloride 
hard lozenges evaluated for physicochemical parameters likehardness, friability, content 
uniformity, weight variation, thickness and drug content, results reported in the table 3.  
The Thickness of the formulations was in the range of 14.23± 0.12 to 14.50± 0.06 cm which 
indicates uniformity for all formulations.. 
Weight variation was found to be in the range of 2.34± 0.12 to 4.51± 0.08%. 
Hardness of the formulations was in the range of 15.95± 0.13 to 16.47± 0.08 kg/cm
2
.  Friability 
was in between 0.93± 0.13 and 0.96± 0.07%. The results of hardness and friability indicated that 
the Carbamazepine lozeges formulations were mechanically stable. 
Drug content was found to be in the range of 95.28± 0.12 to 99.82± 0.52%. 
Disintegration time of all Carbamazepine lozengesformulations lies in between 20±0.3 to 
25±0.2min. Thus, it can be concluded that all the formulations passed physicochemical 
evaluation. In-vitro release study was performed for 30 minutes, results are shown in figure 
1.The percent drug release was found in the range of 55.49 to 93.27%. Carbamazepine lozeges 
formulations of batch CL4 showed a release of 93.27% in 30 minutes, which was relatively 
faster in comparison to the other formulations prepared from ordered mixture, which may be due 
to the presence of Polyethylene glycol 8000, which aid in faster disintegration of the prepared 
lozenges. Since methylcellulose is a hydrophilic polymer, it facilitatesquick release of drug. But 
as the concentration crosses the optimum quantity it retards drug release
15
. 
During stability study of 6 months of selected Carbamazepine lozenges formulations of batch 
CL4, it was observed that the concentrations of drug in all the formulations were decreased a bit, 
within the pharmacopoeia limits.  
It was found that there was a slight change in taste and color of all the lozenges.  
Hence in the stability studies carried for six months it was found that there wasn’t any substantial 
changes in hardness, friability, weight uniformity, % drug content,disintegration time the 
selected formulations were stable throughout the study. 
Table 3: Stability study of Carbamazepine lozenges of batch  CL4 
Time 
(Month) 
Hardness Friability Weight Uniformity %Drug content Disintegration 
time (min) 
0 16.47± 0.08 0.95± 0.18 2.34± 0.12 99.82± 0.52 20±0.3 
2 16.42± 0.06 0.94± 0.07 2.31± 0.23 99.81± 0.03 19.2± 0.05 
4 16.39± 0.11 0.94± 0.06 2.30± 0.05 99.80± 0.02 19± 0.04 
6 16.31± 0.23 0.93± 0.15 2.29± 0.09 99.79± 0.01 18.95± 0.03 
 
  
 
In-vitro drug release profile of Carbamazepine lozenges formulations  
 
Conclusion 
Lozenges enjoy an important position in pharmacy and will continue to remain at the same in 
future. From present study it is concluded thatincorporating polymers like HPMC K4M and 
methylcellulose can be used to formulate effective medicated Carbamazepine lozenges especially 
for patients who cannot swallow solid oral dosage forms like tablet and capsules. This will offer 
better patient compliance and innovative dosage form. Lozenges are intented to slowly dissolve 
in the mouth over a relatively long period of time usually about 2-15 mins or more as needed. By 
incorporation of synthetic polymers yields good results and release thedrugs for a prolonged 
period of 30 mins. Based on different parameters Carbamazepine lozenges formulations of batch 
CL4 can be considered as the optimized formulation. 
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